A twice-yearly injection of Lenacapavir offers a 96% reduced risk of infection overall, making the injection significantly more effective than the daily oral PrEP...
With the injectable antiretroviral drug lenacapavir found to be “safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a...
The findings point to a need for parent-focused messaging through media, the internet and medical providers to answer questions and alleviate concerns parents have...